LongeVC Supports UNP's $32M Series A Funding for AI-Driven Macrocycle Drug Development

LongeVC, Merck Global Health Innovation Fund, and ARTIS Ventures, are some of the investors in the significant $32 million Series A funding round that Unnatural Products, Inc. (UNP) has announced.

This investment supports UNP's innovative AI platform for developing synthetic macrocycles. These macrocycles, designed to mimic natural compounds, present new opportunities for therapeutic applications, particularly in oncology. LongeVC's involvement in this funding round underscores our commitment to investing in groundbreaking healthcare technologies that promise to revolutionise patient care and drug development.

Please refer to the full Unnatural Products, Inc. press release for a comprehensive understanding and further details.